Developed by Johnson & Johnson, guselkumab (GUS) is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.

Biologic disease-modifying antirheumatic drugs (bDMARDs) do not appear to negatively impact fertility among women with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), according to study ...

Initiating methotrexate within 2 years of a psoriasis diagnosis is associated with a reduced risk of progressing to PsA.

TNF inhibitors for the treatment of axial spondyloarthritis may decrease the risk for hip or spine fracture by as much as 29% ...

For patients with rheumatoid arthritis and inadequate response to JAK inhibitors, cycling to another JAK inhibitor is a more effective option than switching to a biological disease-modifying ...

Certain drugs and a host of nonpharmacologic therapies are key to treating patients who have nociplastic pain, a relatively ...

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placeboAchieved statistical significance on key secondary ...

Rheumatoid arthritis (RA) is a chronic autoimmune disease (one in which the immune system attacks healthy cells) that primarily affects your joints. It is a progressive condition that gets worse over ...

1 Division of Rheumatology, Allergy, and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan 2 School of Medicine, College of Medicine, Chang Gung ...

Denosumab Drugs for treatment of bone diseases 2024-05 Celltrion Healthcare Co Ltd Biosimilar Denosumab Drugs for treatment of bone diseases 2024-05 Celltrion Healthcare Co Ltd Biosimilar Denosumab ...

Medically reviewed by Scott Zashin, MD Hair loss is a common side effect of some arthritis medications, including Rheumatrex or Trexall (brand names of methotrexate), Arava (leflunomide), Enbrel ...